Apellis Pharmaceuticals
Price & Volume
Stats
See more52W Range | $16.10-$35.57 |
Market Cap | $3.1B |
Shares Short | 17M |
Financials
See moreRevenue (12 Mos) | $1B |
Revenue Growth (YoY) | 133% |
Gross Profit (12 Mos) | $605M |
Diluted EPS | $0.36 |
News
See moreYahoo Finance • 17 days ago
Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
Yahoo Finance • 25 days ago
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
Yahoo Finance • last month
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges
About
CEO | Dr. Cedric Francois M.D., Ph.D. |
CFO | Mr. Timothy E. Sullivan |
Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 705 |
